UB Paderborn / Katalog / Suche / in CDI

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-11, Vol.25 (6), p.1123-1124

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

British journal of cancer, 2009-05, Vol.100 (9), p.1373-1378

2009

Link zum Volltext

Verfügbarkeit prüfen

Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA)

Current oncology (Toronto), 2018-02, Vol.25 (1), p.e90-94

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s

Annals of oncology, 2018-11, Vol.29, p.ix49-ix50

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma

Annals of oncology, 2008-07, Vol.19 (7), p.1312-1319

2008

Link zum Volltext

Verfügbarkeit prüfen

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

ESMO open, 2021-08, Vol.6 (4), p.100200, Article 100200

2021

Link zum Volltext

Verfügbarkeit prüfen

Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS)

Annals of oncology, 2018-11, Vol.29, p.ix55-ix55

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii137-viii138

2018

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumour DNA experience in patients with cancer of unknown primary

Annals of oncology, 2018-10, Vol.29, p.viii48-viii48

2018

Link zum Volltext

Verfügbarkeit prüfen

Match-adjusted indirect comparison of durvalumab and chemotherapy for locally advanced or metastatic urothelial carcinoma (UC) following failure of platinum-based therapy

Annals of oncology, 2018-10, Vol.29, p.viii323-viii323

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of vorolanib (X-82t vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients (pts) with advanced solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii659-viii660

2018

Link zum Volltext

Verfügbarkeit prüfen

Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii142-viii143

2018

Link zum Volltext

Verfügbarkeit prüfen

PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii20-viii20

2018

Link zum Volltext

Verfügbarkeit prüfen

Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Annals of oncology, 2019-04, Vol.30, p.ii48-ii49

2019

Link zum Volltext

Verfügbarkeit prüfen

Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii516-viii516

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 492

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(475)
Mit Volltextzugriff
(479)

Publikationsform

Sprache

Englisch
(486)
Japanisch
(29)
Deutsch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(181)
Life Sciences & Biomedicine
(178)
Oncology
(143)
Humans
(135)
Male
(83)
Female
(82)
Middle Aged
(79)
Aged
(67)
Adult
(59)
Tumors
(58)
Biological And Medical Sciences
(34)
Metastasis
(34)
Aged, 80 And Over
(33)
Chemotherapy
(33)
Medical Sciences
(33)
Patients
(33)
Cancer Therapies
(28)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(26)
Cancer
(26)
Metastases
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Targeting BRAF for patients with melanoma

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

Reporting incidental germline variants in the context of day-to-day somatic genomic profiling

Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry

The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA)

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS)

Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours

Circulating tumour DNA experience in patients with cancer of unknown primary

Match-adjusted indirect comparison of durvalumab and chemotherapy for locally advanced or metastatic urothelial carcinoma (UC) following failure of platinum-based therapy

A phase I trial of vorolanib (X-82t vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients (pts) with advanced solid tumors

Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors

PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors

Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC)

Suchergebnisse filtern